Left atrial appendage thrombus despite anticoagulation

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The American College of Cardiology Foundation/American Heart Association task force on practice guidelines recommend therapeutic anticoagulation for at least 3 weeks prior to cardioversion in patients with atrial fibrillation of 48-hour duration or longer, or when the duration of atrial fibrillation is unknown. This case report demonstrates the presence of thrombi in the left atrial appendage despite adequate anticoagulation, challenging the current guidelines. Therapeutic anticoagulation for at least 3 weeks followed by transesophageal echocardiography in search of thrombus may enhance thromboembolic safety of elective cardioversion. Atrial fibrillation (AF) and heart failure (HF) have emerged as major cardiovascular epidemics in developed nations over the past decade. They share similar risk factors, seem to mutually accelerate progression and are associated with increased morbidity and mortality. Their relationship involves complex hemodynamic, neuro-hormonal, inflammatory and electrophysiologic mechanisms, which go beyond just mutual risk factors. This review focuses on updates in AF and HF with a hope of better understanding this relationship and the management of this complex duo.

Original languageEnglish (US)
Pages (from-to)11-13
Number of pages3
JournalJournal of Atrial Fibrillation
Volume6
Issue number1
StatePublished - Jun 1 2013

Fingerprint

Atrial Appendage
Atrial Fibrillation
Thrombosis
Electric Countershock
Heart Failure
Transesophageal Echocardiography
Advisory Committees
Practice Guidelines
Developed Countries
Hemodynamics
Guidelines
Morbidity
Safety
Mortality
Therapeutics

Cite this

Left atrial appendage thrombus despite anticoagulation. / Florea, Viorel; Tholakanahalli, Venkatakrishna N; Adabag, Selcuk; Chandrashekhar, Y S.

In: Journal of Atrial Fibrillation, Vol. 6, No. 1, 01.06.2013, p. 11-13.

Research output: Contribution to journalArticle

@article{608c84f8f2684716831cb17f5a881004,
title = "Left atrial appendage thrombus despite anticoagulation",
abstract = "The American College of Cardiology Foundation/American Heart Association task force on practice guidelines recommend therapeutic anticoagulation for at least 3 weeks prior to cardioversion in patients with atrial fibrillation of 48-hour duration or longer, or when the duration of atrial fibrillation is unknown. This case report demonstrates the presence of thrombi in the left atrial appendage despite adequate anticoagulation, challenging the current guidelines. Therapeutic anticoagulation for at least 3 weeks followed by transesophageal echocardiography in search of thrombus may enhance thromboembolic safety of elective cardioversion. Atrial fibrillation (AF) and heart failure (HF) have emerged as major cardiovascular epidemics in developed nations over the past decade. They share similar risk factors, seem to mutually accelerate progression and are associated with increased morbidity and mortality. Their relationship involves complex hemodynamic, neuro-hormonal, inflammatory and electrophysiologic mechanisms, which go beyond just mutual risk factors. This review focuses on updates in AF and HF with a hope of better understanding this relationship and the management of this complex duo.",
author = "Viorel Florea and Tholakanahalli, {Venkatakrishna N} and Selcuk Adabag and Chandrashekhar, {Y S}",
year = "2013",
month = "6",
day = "1",
language = "English (US)",
volume = "6",
pages = "11--13",
journal = "Journal of Atrial Fibrillation",
issn = "1941-6911",
publisher = "Cardiofront, Inc.",
number = "1",

}

TY - JOUR

T1 - Left atrial appendage thrombus despite anticoagulation

AU - Florea, Viorel

AU - Tholakanahalli, Venkatakrishna N

AU - Adabag, Selcuk

AU - Chandrashekhar, Y S

PY - 2013/6/1

Y1 - 2013/6/1

N2 - The American College of Cardiology Foundation/American Heart Association task force on practice guidelines recommend therapeutic anticoagulation for at least 3 weeks prior to cardioversion in patients with atrial fibrillation of 48-hour duration or longer, or when the duration of atrial fibrillation is unknown. This case report demonstrates the presence of thrombi in the left atrial appendage despite adequate anticoagulation, challenging the current guidelines. Therapeutic anticoagulation for at least 3 weeks followed by transesophageal echocardiography in search of thrombus may enhance thromboembolic safety of elective cardioversion. Atrial fibrillation (AF) and heart failure (HF) have emerged as major cardiovascular epidemics in developed nations over the past decade. They share similar risk factors, seem to mutually accelerate progression and are associated with increased morbidity and mortality. Their relationship involves complex hemodynamic, neuro-hormonal, inflammatory and electrophysiologic mechanisms, which go beyond just mutual risk factors. This review focuses on updates in AF and HF with a hope of better understanding this relationship and the management of this complex duo.

AB - The American College of Cardiology Foundation/American Heart Association task force on practice guidelines recommend therapeutic anticoagulation for at least 3 weeks prior to cardioversion in patients with atrial fibrillation of 48-hour duration or longer, or when the duration of atrial fibrillation is unknown. This case report demonstrates the presence of thrombi in the left atrial appendage despite adequate anticoagulation, challenging the current guidelines. Therapeutic anticoagulation for at least 3 weeks followed by transesophageal echocardiography in search of thrombus may enhance thromboembolic safety of elective cardioversion. Atrial fibrillation (AF) and heart failure (HF) have emerged as major cardiovascular epidemics in developed nations over the past decade. They share similar risk factors, seem to mutually accelerate progression and are associated with increased morbidity and mortality. Their relationship involves complex hemodynamic, neuro-hormonal, inflammatory and electrophysiologic mechanisms, which go beyond just mutual risk factors. This review focuses on updates in AF and HF with a hope of better understanding this relationship and the management of this complex duo.

UR - http://www.scopus.com/inward/record.url?scp=84882675133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882675133&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84882675133

VL - 6

SP - 11

EP - 13

JO - Journal of Atrial Fibrillation

JF - Journal of Atrial Fibrillation

SN - 1941-6911

IS - 1

ER -